Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M71,082Revenue $M10,299Net Margin (%)33.9Altman Z-Score12.9
Enterprise Value $M69,293EPS $14.8Operating Margin %45.1Piotroski F-Score9
P/E(ttm)20.5Beneish M-Score-2.2Pre-tax Margin (%)44.8Higher ROA y-yY
Price/Book5.610-y EBITDA Growth Rate %26.5Quick Ratio1.9Cash flow > EarningsY
Price/Sales6.95-y EBITDA Growth Rate %25.5Current Ratio2.2Lower Leverage y-yY
Price/Free Cash Flow22.1y-y EBITDA Growth Rate %44.7ROA % (ttm)23.9Higher Current Ratio y-yY
Dividend Yield %--PEG0.8ROE % (ttm)31.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M235ROIC % (ttm)36.6Gross Margin Increase y-yY

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBVanguard Health Care Fund 2015-06-30 Add1.17%$373.93 - $430.96
($401.66)
$ 299.78-25%Add 425.02%1,780,330
BIIBMario Gabelli 2015-06-30 Reduce$373.93 - $430.96
($401.66)
$ 299.78-25%Reduce 2.74%4,797
BIIBKen Fisher 2015-06-30 Reduce$373.93 - $430.96
($401.66)
$ 299.78-25%Reduce 0.16%80,932
BIIBVanguard Health Care Fund 2015-03-31 Buy 0.31%$334.65 - $475.98
($394.14)
$ 299.78-24%New holding339,100
BIIBJoel Greenblatt 2015-03-31 Sold Out -0.014%$334.65 - $475.98
($394.14)
$ 299.78-24%Sold Out0
BIIBMario Gabelli 2015-03-31 Reduce$334.65 - $475.98
($394.14)
$ 299.78-24%Reduce 0.06%4,932
BIIBKen Fisher 2015-03-31 Add$334.65 - $475.98
($394.14)
$ 299.78-24%Add 2.28%81,058
BIIBKen Heebner 2014-12-31 Sold Out -0.75%$299.1 - $360.67
($323.29)
$ 299.78-7%Sold Out0
BIIBVanguard Health Care Fund 2014-12-31 Sold Out -0.2%$299.1 - $360.67
($323.29)
$ 299.78-7%Sold Out0
BIIBJoel Greenblatt 2014-12-31 Reduce-0.08%$299.1 - $360.67
($323.24)
$ 299.78-7%Reduce 84.03%5,012
BIIBKen Heebner 2014-09-30 Buy 0.75%$299.29 - $346.3
($329.79)
$ 299.78-9%New holding80,000
BIIBVanguard Health Care Fund 2014-09-30 Reduce-0.27%$299.29 - $346.3
($329.79)
$ 299.78-9%Reduce 58.26%233,600
BIIBJoel Greenblatt 2014-09-30 Buy 0.1%$299.29 - $346.3
($329.79)
$ 299.78-9%New holding31,391
BIIBKen Heebner 2014-06-30 Sold Out -0.95%$274 - $320.13
($300.74)
$ 299.78-0%Sold Out0
BIIBKen Fisher 2014-06-30 Add0.05%$274 - $320.13
($300.74)
$ 299.78-0%Add 386.61%88,885
BIIBVanguard Health Care Fund 2014-06-30 Reduce-0.03%$274 - $320.13
($301.05)
$ 299.78-0%Reduce 6.62%559,700
BIIBJoel Greenblatt 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 299.78-0%Sold Out0
BIIBGeorge Soros 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 299.78-0%Sold Out0
BIIBRon Baron 2014-06-30 Add$274 - $320.13
($300.74)
$ 299.78-0%Add 41.76%8,632
BIIBMario Gabelli 2014-06-30 Add$274 - $320.13
($301.05)
$ 299.78-0%Add 16.46%4,175
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PAPADOPOULOS STELIOSDirector 2015-07-27Buy10,000$304.88-1.67view
Posner Brian SDirector 2015-06-22Sell470$415-27.76view
WILLIAMS DOUGLAS EEVP Research & Development 2015-06-19Sell3,841$410-26.88view
Posner Brian SDirector 2015-06-15Sell400$386.64-22.47view
SCANGOS GEORGE ACEO 2015-06-01Sell1,362$398.87-24.84view
SCANGOS GEORGE ACEO 2015-05-01Sell1,362$377.52-20.59view
SCANGOS GEORGE ACEO 2015-04-01Sell1,362$423.2-29.16view
Sandrock AlfredGrp SVP, Chief Medical Officer 2015-03-27Sell430$430.12-30.3view
Cox JohnEVP Pharmaceutical Oper & Tech 2015-03-25Sell12,010$449.06-33.24view
Rowinsky Eric KDirector 2015-03-20Sell11,667$475-36.89view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about biib:

Articles On GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class A Aug 20 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
Investment Strategies for the Bullish Biotech Sector Jun 01 2015 
Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
PRIMECAP Sells Portions of Its Top Two Stakes May 27 2015 

More From Other Websites
Biogen's IT Overhaul Aims to Bring in Emerging Tech to Expand Business Sep 04 2015
This Stock May be the Best Opportunity in Biotech Sep 04 2015
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Sep 03 2015
Kyle Bass is slamming the group blocking his new, big short strategy Sep 03 2015
After Biogen deal, Florida biotech opening Cambridge office Sep 03 2015
Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors Sep 03 2015
Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors Sep 03 2015
USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl... Sep 02 2015
Biogen Wins Round In Patent Fight Vs. Kyle Bass Sep 02 2015
Biogen patent survives challenge by hedge fund manager Kyle Bass Sep 02 2015
Amgen, Novartis Alzheimer's Deal Gets Cautious Praise Sep 02 2015
Biogen: 'A Nice Little Trade' Or Heading To New Lows? Sep 01 2015
Jim Cramer -- A Fed Rate Hike Won't Stop Profit Opportunities Sep 01 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of Pendency of Class... Sep 01 2015
Gilead Sciences: Most Enticing Sep 01 2015
A Hidden Biotech Marvel Sep 01 2015
Coverage initiated on Biogen by Raymond James Sep 01 2015
BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Sep 01 2015
Applied Genetic Meets Enrolment Milestone in XLRS Study Aug 31 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK